Evidence map›Paper›PMID 28764661›Full record

ArticleBMC infectious diseases2017

HIV testing week 2015: lowering barriers for HIV testing among high-risk groups in Amsterdam.

M Bartelsman, I K Joore, J E van Bergen, A A Hogewoning, F R Zuure, M G van Veen, HIV Transmission Elimination AMsterdam (H-TEAM) initiative

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

M BartelsmanSTI Outpatient Clinic, Public Health Service of Amsterdam (GGD Amsterdam), Amsterdam, the Netherlands. mbartelsman@ggd.amsterdam.nl.ORCID 0000-0003-3347-9508
I K JooreDepartment of General Practice/Family Medicine, Division of Clinical Methods and Public Health, Academic Medical Center, Amsterdam, the Netherlands.
J E van BergenDepartment of General Practice/Family Medicine, Division of Clinical Methods and Public Health, Academic Medical Center, Amsterdam, the Netherlands.
A A HogewoningSTI Outpatient Clinic, Public Health Service of Amsterdam (GGD Amsterdam), Amsterdam, the Netherlands.
F R ZuureDepartment of Infectious Diseases Research and Prevention, Public Health Service of Amsterdam (GGD Amsterdam), Amsterdam, the Netherlands.
M G van VeenSTI Outpatient Clinic, Public Health Service of Amsterdam (GGD Amsterdam), Amsterdam, the Netherlands.
HIV Transmission Elimination AMsterdam (H-TEAM) initiative
Amsterdam UMC Location University of Amsterdam · NLGGD Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvaluation of the HIV Testing Week (HTW) 2015 in Amsterdam: the number of (positive) tested persons, characteristics and testing history of the tested population, the differences in attendance per location and the healthcare workers' experiences and opinions concerning the HTW.

methodsThe HTW took place from 28 November till 4 December 2015. Anonymous HIV rapid testing (INSTI™ HIV1/HIV2 Ab test or Determine™ HIV-1/2 Ag/Ab test) was offered free of charge at four hospitals, 12 general practitioner (GP) clinics, a sexually transmitted infections (STI) clinic, a laboratory, sites of a community-based organisation, and at outreach locations. Home-based testing (OraQuick® In-Home HIV Test) was offered online. The focus was to motivate two groups to test: men who have sex with men (MSM) and non-Western migrants. Questionnaires regarding participant's characteristics and HIV testing history were collected. Also healthcare workers were asked to complete a questionnaire evaluating the HTW.

resultsIn total, 1231 participants were tested. With three positive HIV tests, the detection rate was 0.3% (95%CI 0.26-0.37). Of all participants, 24.7% (304/1231) were MSM. Respectively, 22.3% (275/1231) and 15.7% (193/1231) were first- and second-generation migrants from a non-Western country. Altogether, 56.7% (698/1231) of participants belonged to one of the targeted risk groups. For 32.7% (402/1231) of participants, it was the first time they received testing, and 35.1% (432/1231) were tested more than 1 year ago. Among MSM 13.2% were tested for the first time, among first- and second-generation non-Western migrants this percentage was significantly higher at 27.2% and 33.5% respectively (p < 0.01). The number of tested participants per location varied widely, especially between GP clinics (range 3-63). Healthcare workers were positive about the HTW: about half (46.2%) stated they would more readily offer an HIV test following their experience with the HTW.

conclusionsThis was the first time the Amsterdam HTW was organised on such a large scale. The majority of the tested population belonged to one of the targeted risk groups and received testing either for the first time or for the first time in over a year. It is important to further build upon the experiences of the HTW and offer free of charge low-threshold HIV testing more structurally. An evaluation of cost-effectiveness is also warranted for future editions of the HTW.

Indexed as

Mass ScreeningAdolescentAdultAgedAged, 80 and overCost-Benefit AnalysisFemaleHIV-1HIV-2HIV InfectionsHomosexuality, MaleHumansMaleMiddle AgedNetherlandsSurveys and QuestionnairesHIVHIV testing weekMigrantsMsmPoint-of-care testRapid test

Identifiers

PMID28764661
PMCPMC5540217
OpenAlexW2741921344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.